Navigation Links
ANA598 Demonstrates Positive 4-Week Results at 200 mg BID
Date:12/17/2009

3.7 3.9

No patient experienced viral rebound (defined as >1 log10 increase from a prior measurement) through week 4. In accordance with the study protocol, four patients (three genotype 1a patients receiving placebo plus SOC and one genotype 1b patient receiving ANA598 plus SOC) discontinued either ANA598 or placebo at week 4 due to failing to reach at least 1 log10 viral load decline.

Preliminary Safety Assessment

Safety and tolerability from the interim analysis appeared similar between the active and placebo arms, with reported adverse events generally typical for interferon and ribavirin, although conclusions regarding longer-term safety and tolerability cannot be made until additional results over longer duration from this trial and future clinical trials in more patients are known. There were no discontinuations due to adverse events. Eight patients reported rash through the interim analysis date, seven mild and one moderate. For the six of twenty-nine patients (21%) receiving ANA598 plus SOC who reported rash, all cases were mild. For the two of fifteen patients (13%) receiving placebo plus SOC who reported rash, one case was mild and one case was moderate. There were no clinically meaningful changes in safety laboratory values and no changes in safety monitoring were recommended by the DMC in association with escalation to 400 mg bid.

Phase II Combination Study

In the ongoing Phase II study, treatment-naïve genotype 1 patients are to receive ANA598 or placebo in combination with Pegasys® (peginterferon alfa-2a) and Copegus® (ribavirin, USP) for 12 weeks at dose levels of 200 mg or 400 mg both given twice daily (bid), each with a loading dose of 800 mg bid on day one. After week 12, patients are to continue receiving SOC. Patients who achieve undetectable levels of virus at weeks 4 and 12 will be randomized to stop all treatment at week 24 or 48.
'/>"/>

SOURCE Anadys Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
2. Anadys Pharmaceuticals Announces Positive Results for ANA598 in Animal Model of Chronic Hepatitis C Virus Infection
3. Anadys Pharmaceuticals Presents Data on ANA598, a Non-Nucleoside Inhibitor of the HCV Polymerase, at the 21st International Conference on Antiviral Research
4. Anadys Pharmaceuticals Initiates Phase I Clinical Trial of ANA598
5. Anadys Pharmaceuticals Announces Successful Outcome of ANA598 Healthy Volunteer Study and Finalization of Study Design for Phase Ib Trial in HCV Patients
6. Anadys Pharmaceuticals Announces Single Dose Safety and Pharmacokinetics Results for ANA598 in Healthy Volunteers
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
9. Anadys Pharmaceuticals Commences Dosing in Phase II Study of ANA598
10. Cytokine Demonstrates Oral Efficacy of Small-Molecule MIF Inhibitors
11. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... , Jan. 23, 2015 A lot of discussion in ... for treating  certain illnesses, injuries, or conditions. As medical science ... treatment methods with ones that they consider to be more ... is not one textbook method of treatment that stands out ...
(Date:1/23/2015)... , Jan. 23, 2015  A new analysis of ... D 2015 enrollment data shows that 81 percent of ... access and extra discounts at certain pharmacies. The findings ... "Preferred pharmacy plans are now the foundation of Medicare ...
(Date:1/23/2015)... 2015 More than a third of reproductive-aged women enrolled ... private insurance, filled a prescription for an opioid pain medication ... week,s Morbidity and Mortality Weekly Report (MMWR). ... moderate to severe pain.  They are also found in some ...
Breaking Medicine Technology:No One-Size-Fits-All Remedy for Hernia Correction 2New Analysis: 81 Percent of Medicare Part D Seniors Choose "Preferred Pharmacy" Plans in 2015 2Opioid painkillers widely prescribed among reproductive age women 2Opioid painkillers widely prescribed among reproductive age women 3
... Calif. , June 3 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... will present during the Jefferies 2010 Global Life Sciences Conference.  The Alexza presentation ... ET .  The presentation will be webcast from the Grand Hyatt Hotel in ... , To ...
... ViroPharma Incorporated (Nasdaq: VPHM ) today announced that William Roberts ... Global Life Sciences Conference at 4:00 P.M. ET on Wednesday, ... in New York City . , ... Mr. Roberts also will present at the ThinkEquity Healthcare Conference at 1:30 ...
Cached Medicine Technology:Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference 2Alexza Pharmaceuticals to Present at Jefferies 2010 Global Life Sciences Conference 3ViroPharma to Participate in Two June Healthcare Investor Conferences 2
(Date:1/22/2015)... Minn. (PRWEB) January 22, 2015 Blue Cross ... those Minnesotans who exemplify what it means to “Live Fearless.” ... chance for people to share their stories about how they ... or simply inspired others by living in the moment. By ...
(Date:1/22/2015)... 2015 Thousand of GranuFlo lawsuits ( ... its GranuFlo and NaturaLyte dialysis concentrates continue to move ... District Court, District of Massachusetts, Bernstein Liebhard LLP reports. ... has remanded a case filed by the state of ...
(Date:1/22/2015)... January 22, 2015 A study ... Medicine flagship journal Medicine & Science in Sports ... exercise may help reduce gastrointestinal (GI) problems associated ... , Participants in the double-blind, placebo-controlled study took ...
(Date:1/22/2015)... Payday lending practices in four southern states worsen ... to the states that permit them, according to a ... Race and Wealth. , While they generate hundreds of ... the same time substantially depress economic activity, according to ...
(Date:1/22/2015)... 22, 2015 Lower-Auto-Insurance.com has released a new blog ... a car for reducing the costs of an auto insurance ... be able to get lower prices for their vehicle insurance policies. ... role in determining policy costs. Because of this, drivers should ...
Breaking Medicine News(10 mins):Health News:Blue Cross and Blue Shield of Minnesota to Showcase “Faces of Fearless” 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 3Health News:Court Overseeing Federal GranuFlo Lawsuits Remands Louisiana Claim Back to State Court, Bernstein Liebhard LLP Reports 4Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 2Health News:Study Shows Kyowa Hakko’s L-Citrulline May Help Reduce Gastrointestinal Injury During Strenuous Exercise 3Health News:Howard University Spotlights the Economic Impact of Payday Lending in Southern States 2Health News:Driving Safe And Other Factors That Make Auto Insurance Affordable! 2
... painkillers, especially the likes of Ibuprofen and Aspirin, which come ... out or exercise. A new study has suggested that the ... work out, may ease muscle pain by 50%. ... of kinesiology at the University of Georgia, Athens, 'A lot ...
... is only too happy to perform it. ... had been diagnosed with X-linked lymphoproliferative syndrome, //a rare genetic ... affected around 100 males worldwide. ,Life expectancy ... causes the immune system to respond abnormally to some viral ...
... San Antonio, Texas has come to the rescue of a ... choice. ,This clinic aids couples who are interested ... to choose the egg //and sperm donors. The couple after ... adults decides accordingly. The complete history of the donors is ...
... books, including old and rare manuscripts on the ancient Indian ... be built at the National Ayurveda Institute at a cost ... biggest ayurveda libraries in India. It will house national and ... information under one roof. ,'The budget has already ...
... at Monash University in Australia have developed a process for ... without any moving parts, potentially allowing doctors //to do blood ... new method uses the same principle that causes tea leaves ... stirred teacup, a phenomenon first explained by Einstein in the ...
... Publishing are excited to announce the publication of the ... issue of Wound Repair and Regeneration (WRR), the premier ... continued interest by the WHS membership and with a ... developed to establish guidelines for the treatment of chronic ...
Cached Medicine News:Health News:Work-outs, Not So Much of a ‘pain’ With Caffei 2Health News:Big Brother to the Rescue 2Health News:Einstein's Tea Leaves Inspire New Blood Separation Technique 2
... ENA assays can be used to ... antibodies, which are associated with various ... lupus erythematosus (Lupus), Sjgren's syndrome, mixed ... scleroderma, polymyositis, dermatomyositis, and Raynaud's phenomenon. ...
... commonly prescribed for the prevention of life threatening ... However, a number of studies have shown that ... aspirin therapy to prevent a recurrent vascular event ... These people are at greater risk for a ...
... System is an embolic protection device that ... debris that may be dislodged during interventional ... components. The first is a guidewire-mounted filter, ... Other ancillary components supplied with the system ...
... is a simulator for intraocular surgery. The ... surgeon the feeling that he is experiencing ... surgeon uses instruments that feel and function ... through the EYESI microscope is similar to ...
Medicine Products: